Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 12:58 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 101 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: PERSERIS Clear all

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: ZX003 (Risperidone-SABER®), Risperdal Consta, Oral Risperidone; Drug
Lead sponsor: Zogenix, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Healthy
Interventions: Risperidone; Drug
Lead sponsor: Ranbaxy Laboratories Limited; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Schizophrenia
Interventions: Aripiprazole, Risperidone; Drug
Lead sponsor: Kettering Health Network; Other
Eligibility: 18 Years to 55 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Kettering, Ohio

Conditions: Psychotic Disorders, Schizophrenia, Bipolar Disorder, Depressive Disorder
Interventions: Aripiprazole, oral formulation, Olanzapine, oral formulation, Paliperidone, oral formulation, Paliperidone, LAI, Quetiapine, oral formulation, Risperidone, oral formulation, Risperidone, LAI; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 305 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 6
States / cities: Garden Grove, California • Kissimmee, Florida • Atlanta, Georgia + 3 more

Conditions: Schizophrenia
Interventions: PERSERIS, Risperidone; Drug
Lead sponsor: Indivior Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Garden Grove, California

Conditions: Aggression, Attention Deficit-Hyperactivity, Oppositional Defiant Disorder, Pervasive Development Disorders, Bipolar Disorder
Interventions: risperidone, olanzapine, aripiprazole; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 6 Years to 18 Years
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Cocaine-Related Disorders, Substance-Related Disorders
Interventions: Risperidone, Placebo, Relapse prevention counseling; Drug · Behavioral
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 60 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 1999
U.S. locations: 1
States / cities: New York, New York

Conditions: Psychotic Disorders
Interventions: Aripiprazole or Perphenazine, Metformin, Olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone, paliperidone, or olanzapine/fluoxetine; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 8 Years to 19 Years
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 4
States / cities: Baltimore, Maryland • Glen Oaks, New York • Chapel Hill, North Carolina

Conditions: Bipolar Disorder
Interventions: Lithium Carbonate, Lamotrigine, Valproic Acid, Oxcarbazepine, Carbamazepine, Ziprasidone, Risperidone, Quetiapine, Olanzapine, Aripiprazole, Fluoxetine / Olanzapine, Haloperidol, Perphenazine, Clozapine, Asenapine, Lurasidone, Paliperidone, Mirtazapine, Bupropion, Desvenlafaxine, Duloxetine, Venlafaxine, Citalopram, Escitalopram, Fluoxetine, Fluvoxamine, Paroxetine, Sertraline, Vilazodone, Doxepin; Drug
Lead sponsor: University of New Mexico; Other
Eligibility: Not listed
Enrollment: 1,037,352 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Opioid Abuse, Unspecified, Opioid Dependence
Interventions: Oxycodone/Placebo, Oxycodone/Risperidone, Oxycodone/Ziprasidone; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 21 Years to 65 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Schizophrenia
Interventions: risperidone (RISPERDAL CONSTA); Drug
Lead sponsor: Janssen, LP; Industry
Eligibility: 18 Years and older
Enrollment: 532 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Stress Disorders, Post-Traumatic
Interventions: Risperidone, Placebo; Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older
Enrollment: 296 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 20
States / cities: Tuscaloosa, Alabama • San Diego, California • San Francisco, California + 17 more

Conditions: Schizophrenia
Interventions: ASP4345, placebo, risperidone, quetiapine, olanzapine, ziprasidone, aripiprazole, brexpiprazole, paliperidone, lurasidone; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 27
States / cities: Cerritos, California • Garden Grove, California • Lemon Grove, California + 19 more

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Risperdal Consta; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 55 Years
Timeline: Started 2005
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Obsessive-Compulsive Disorder
Interventions: Risperidone, Exposure/ritual prevention therapy (EX/RP), Placebo; Drug · Behavioral
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 70 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 2
States / cities: New York, New York • Philadelphia, Pennsylvania

Conditions: Schizophrenia
Interventions: paliperidone palmitate, oral risperidone; Drug
Lead sponsor: Ortho-McNeil Janssen Scientific Affairs, LLC; Industry
Eligibility: 18 Years to 35 Years
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 23
States / cities: Little Rock, Arkansas • Garden Grove, California • San Diego, California + 20 more

Conditions: Bipolar Disorder
Interventions: Risperidone oral solution, Valproate Oral Solution, Placebo; Drug · Other
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 3 Years to 7 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 2
States / cities: Cincinnati, Ohio • Milwaukee, Wisconsin

Conditions: Weight, Body
Interventions: Risperidone, Aripiprazole; Drug
Lead sponsor: Duke University; Other
Eligibility: 3 Years to 18 Years
Enrollment: 509 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 37
States / cities: Dothan, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 32 more

Conditions: Attention Deficit Disorder With Hyperactivity
Interventions: Methylphenidate HCl, Risperidone, Parent Management Training (PMT), Placebo; Drug · Behavioral
Lead sponsor: Michael Aman; Other
Eligibility: 6 Years to 12 Years
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 4
States / cities: Stony Brook, New York • Cleveland, Ohio • Columbus, Ohio + 1 more

Conditions: Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorder Not Otherwise Specified
Interventions: long-acting injectable risperidone; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 15 Years to 40 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 2
States / cities: Brooklyn, New York • Glen Oaks, New York

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Risperidone, Olanzapine, Quetiapine, Aripiprazole; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 215 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 28
States / cities: Colton, California • Palo Alto, California • New Haven, Connecticut + 25 more

Conditions: Healthy
Interventions: Risperidone; Drug
Lead sponsor: Ranbaxy Laboratories Limited; Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Sexual Dysfunction
Interventions: Abilify Maintena; Drug
Lead sponsor: Gazda, Thomas D., M.D., PC; Individual
Eligibility: 18 Years to 40 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Bullhead City, Arizona

Conditions: Addiction
Interventions: Risperidone, Ziprasidone, Oxycodone; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 21 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: San Antonio, Texas

Search by objective public record fields.

Safety and PK Trial With Injectable ZX003 (Risperidone-SABER®) Compared to Risperdal® Consta® in Stable Schizophrenia

Bioequivalence Study of Risperidone 1 mg Orally-disintegrating Tablets Under Fed Conditions

Best Event Schizophrenia Trial--A Randomized Double-Blind Trial of Aripiprazole and Risperidone in Schizophrenia

Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants

Safety, Tolerability, Pharmacokinetics and Efficacy of 180 mg Subcutaneous Risperidone From 6 mg Oral Risperidone

Metabolic Effects of Antipsychotics in Children

Early Phase II Trials for Cocaine Medication Development - 1

Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics

Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies

Reducing the Abuse of Opioids in Drug Users

Observational Study in Patients With Schizophrenia Treated With Long-Acting Risperidone Injection (RISPERDAL CONSTA)

Risperidone Treatment for Military Service Related Chronic Post Traumatic Stress Disorder

A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication

Risperdal Consta and Health Care Utilization in Patients With Schizophrenia

Risperidone or Cognitive-Behavioral Therapy for Improving Medication Treatment for Obsessive-compulsive Disorder

28-30 Month Study Comparing Paliperidone Palmitate With Oral Risperidone for Treating Adults Diagnosed With Schizophrenia Within the Past 5 Years

Placebo Controlled Trial of Valproate and Risperidone in Young Children With Bipolar Disorders

Long-term Antipsychotic Pediatric Safety Trial

Treatment of Severe Childhood Aggression (The TOSCA Study)

Optimizing Response in Psychosis Study

Comparison of Antipsychotics for Metabolic Problems in Schizophrenia or Schizoaffective Disorder

Bioequivalence Study of Risperidone 1 mg Orally-disintegrating Tablets Under Fasting Conditions

Aripiprazole, Abilify Maintena Collaborative Clinical Protocol

Reducing the Abuse Liability of Prescription Opioids